Orelabrutinib( higher dose) ( DrugBank: Orelabrutinib )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
63特発性血小板減少性紫斑病1

63. 特発性血小板減少性紫斑病


臨床試験数 : 391 薬物数 : 235 - (DrugBank : 50) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 139
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05232149
(ClinicalTrials.gov)
February 21, 202220/12/2021A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune ThrombocytopeniaA Randomized, Multi-center, Adaptive Phase IIa/IIb Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Persistent or Chronic Primary Immune ThrombocytopeniaPrimary Immune ThrombocytopeniaDrug: Orelabrutinib( lower dose);Drug: Orelabrutinib( higher dose)Beijing InnoCare Pharma Tech Co., Ltd.NULLRecruiting18 Years80 YearsAll30Phase 2China